CDMO Rentschler Biopharma and Coriolis Pharma, a CRDO, say they agreed to offer clients end-to-end solutions from early formulation through to commercial manufacturing by combining their complementary skills. Coriolis Pharma brings a combination of in silico and wet lab formulation and drug product development expertise, scientific depth, and advanced analytical capabilities to this collaboration, according to Silvia Steyrer-Gruber, CEO of the company.
Rentschler Biopharma brings experience in bioprocess development and manufacturing for multiple biotherapeutics, noted Benedikt von Braunmühl, Rentschler Biopharma’s CEO.
“By bringing together our individual areas of excellence, bioprocess development and manufacturing on our side, and scientific and analytical expertise in formulation development at Coriolis, we look forward to addressing complex challenges across the biopharmaceutical value chain more efficiently and faster,” said Braunmühl.
“Together, we can provide clients with connected, science-driven solutions that help them move their projects forward towards success,” added Steyrer-Gruber.
The integrated service offering will be available to clients starting this month. Both organizations have operations in Germany and the U.S.
